Pharmacoeconomic considerations with statin therapy

Bibliography

• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVIAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet (1994) 344:1383-1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MAYE LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. (1996) 335:1001-9.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1349-1357.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7-22.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Prospective study of pravastatin in the elderly at risk. Pravastatin in the elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet (2002) 360:1623-1630.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, GRUNDY SM, WATERS DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352:1425-1435.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al. for the West of Scotland Coronary Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301-1307.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al. for the AFCAPS/TexCaps Research Group: Primary prevention of acute coronary syndromes with lovastatin in men and women with average cholesterol levels. JAMA (1998) 279:1615-1622.
   PubMed Web of Science ®Google Scholar
• THE ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid Lowering Treatment to prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288:2998-3007.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet (2003) 361:1149-1158.
   PubMed Web of Science ®Google Scholar
• CALHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet (2004) 364:685-696.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR, FAERGEMAN O, KASTELEIN JJ et al.: High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA (2005) 294:2437-2445.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators: effects of atorvastatin on early recurrent ischemic events in acute coronary syndrome: the MIRACLE study: a randomized controlled trial. JAMA (2001) 285(13):1711-1718.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350:1495-1504.
   PubMed Web of Science ®Google Scholar
• DE LEMOS JA, BLAZING MA, WIVIOTT SD et al.: Early invasive versus a delaved conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 292:1307-1316
   PubMed Web of Science ®Google Scholar
• MITKA M: Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA (2003) 290(17):2243-2245.
   Google Scholar
• TSEVAT J, KUNTZ KM, ORAV EJ et al.: Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am. Heart J. (2001) 141:727-34
   PubMed Web of Science ®Google Scholar
• JOHANNESSON M, JONSSON B, KJEKSHUS J et al.: Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N. Engl. J. Med. (1997) 336(5):332-336.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20 536 individuals. Lancet (2005) 365:1779-1785.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GG, GANZ P, WATERS D, ARIKAN S: Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am. J. Cardiol. (2003) 92:1109-1112.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J: Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am. J. Cardiol. (2001) 87(suppl):19B-22B.
   Google Scholar
• GOTTO AM, BOCCUZZI SJ, COOK JR et al.: Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas coronary atherhosclerosis prevention study. Am. J. Cardiol. (2000) 86:1176-1181
   PubMed Web of Science ®Google Scholar
• LINDGREN P, BUXTON M, KAHAN T et al.: Cost-effectiveness of atorvastatin in the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial–lipid lowering arm (ASCOT-LLA). Eur. J. Cardiovasc. Prev. Rehabil. (2005) 12:29-36.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, BAIREY-MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation (2004) 110:227-239.
   PubMed Web of Science ®Google Scholar
• HILLEMAN DE, PHILLIPS JO, MOHIUDDIN SM et al.: A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin. Ther. (1999) 21:536-552.
   PubMedGoogle Scholar
• CHONG PH, VARNER D: Cost-efficacy of 3-hydroxy-3-methylglutaryl coenzyme inhibitors based on the results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy (2005) 25:270-278.
   PubMedGoogle Scholar
• HIRSCH M, O’DONNELL JC, JONES P: Rosuvastatin is cost -effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin, and simvastatin: analysis of the STELLAR trial. Eur. J. Cardiovasc. Prev. Rehabil. (2005) 12:18-28.
   PubMed Web of Science ®Google Scholar
• HIRSCH M, O’DONNELL J, OLSSON A: Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int. J. Cardiol. (2005) 104:251-256.
   PubMedGoogle Scholar
• MARK DB, HLATKY MA: Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation (2002) 106:516-520.
   PubMed Web of Science ®Google Scholar
• PRICE-CHEK PC (2006) MediSpan; Wolters Kluwer Health Inc, Indianapolis, IN.
   Google Scholar